查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999359

肝癌诊断市场：2026年至2032年全球市场预测，依分期、检测类型、技术及最终用户划分

Liver Cancer Diagnostics Market by Disease Stage, Test Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肝癌诊断市场价值将达到 107 亿美元，到 2026 年将成长至 113.8 亿美元，到 2032 年将达到 169.7 亿美元，复合年增长率为 6.81%。

主要市场统计数据
基准年 2025 107亿美元
预计年份：2026年 113.8亿美元
预测年份 2032 169.7亿美元
复合年增长率 (%) 6.81%

简要概述正在重新定义肝癌治疗诊断路径和相关人员优先事项的临床、技术和政策驱动因素的演变。

肝癌诊断领域正经历快速发展，其驱动力包括技术创新、临床实践的变革以及政策趋势的转变。本执行摘要概述了影响诊断路径、诊断方法应用以及相关人员决策的最重要趋势。接下来的章节将对临床趋势、监管影响、技术成熟度和营运限制进行综合分析，揭示这些因素如何塑造诊断领域相关人员所处的竞争格局和临床环境。

分子诊断、影像解析度和保险公司可接受的证据创建方面的创新融合如何改变肝癌诊断途径。

一系列变革正在重塑我们对肝癌的检测、表征和治疗方式。分子诊断和高灵敏度成像技术的进步使临床医生能够在疾病早期进行干预，提高肿瘤表征的准确性，同时减少对高侵入性操作的依赖。同时，循环肿瘤DNA (ctDNA) 和微型RNA(miRNA) 检测与已建立的蛋白质标记的整合，正在促进混合诊断策略的发展，从而在不同的临床环境中平衡灵敏度和操作可行性。

我们将评估近期关税调整对诊断服务和技术整体的筹资策略、供应商选择和资本分配决策的影响。

2025年关税的实施和贸易政策的调整，为诊断耗材、影像设备和分子检测平台的筹资策略增添了新的变数。供应链经理和采购人员正在透过重新评估采购区域、协商长期供应商合约以及考虑本地组装和检验的二级供应商等方式来应对这些变化，以降低进口关税及其导致的成本波动带来的风险。

详细的細項分析揭示了疾病进展、医疗保健环境、实验室架构和成像方式如何共同决定诊断技术的采用模式和投资重点。

基于细分的洞察揭示了疾病进展各阶段、终端用户画像、检测类型和技术模式的清晰需求和运作模式。就疾病进展而言，晚期流程优先考虑确诊性检测和分子谱分析，以指南标靶治疗；而早期流程则优先考虑高灵敏度筛检技术和微创诊断，以支持根治性介入。这种二分法导致了侵入性和非侵入性检测方式的采用曲线存在差异。

对比区域趋势，可以发现医疗保健基础设施、报销途径和资本投资如何影响全球主要市场诊断技术的采用。

区域趋势呈现出显着的异质性，这源自于医疗基础设施、法规结构、报销机制和临床实践模式的差异。在美洲，诊断生态系统强调在连网医疗系统和学术机构内快速采用创新技术，推动了三级医疗和门诊诊断网路对整合分子和影像解决方案的需求。该地区通常在将临床试验证据转化为临床实践方面发挥主导作用，对先进的分子谱分析以支持精准肿瘤学研究表现出强烈的需求。

竞争和合作趋势表明，一体化的产品组合、强大的实证策略和供应链韧性将决定诊断市场的长期定位。

肝癌诊断领域的竞争格局由成熟的诊断试剂製造商、专业的分子诊断公司、影像设备供应商和临床实验室网路组成。市场领导凭藉其广泛的产品组合保持差异化优势，这些产品组合涵盖影像硬体、检测试剂盒以及用于数据解读和工作流程整合的整合软体解决方案。中型企业和创新Start-Ups则透过开发针对特定领域的检测方法、次世代定序(NGS) 应用以及微创生物标记组合，为满足早期检测和分子分型方面尚未满足的需求做出贡献。

为产品、临床和销售团队制定可操作的策略重点，以加速产品推广、降低供应风险并展现可持续的临床价值。

产业领导者应优先考虑制定一致的策略，协调产品开发、临床证据产生和上市时间模式，以最大限度地提高临床应用率和商业性吸引力。投资进行前瞻性研究，以证明其在早期检测和治疗分层方面的临床效用，预计将对指南采纳和支付方支持产生重大影响。同时，应为门诊诊所、诊断中心、医院和实验室制定客製化的实施蓝图，以确保解决方案能够根据各机构的实际情况进行最佳化。

采用混合方法研究途径，结合专家访谈、临床文献整合和技术评估，以检验操作和临床见解。

本分析采用混合方法，兼顾定量检验和定性情境化，整合一手和二手资讯。一级资讯来源包括对临床专业人员、实验室经理、采购经理和产业高管的访谈，以了解实际营运和策略意图。这些观点经过系统编码，以识别诊断技术应用、工作流程整合和支付方参与的共同主题。

结论强调了在证据生成、工作流程整合和供应弹性方面的合作投资将如何塑造诊断领域的领导地位。

总之，肝癌的诊断格局正朝着整合式、多模态方法转变，力求在所有医疗机构中平衡敏感性、特异性和操作可行性。基因组检测和影像技术的进步不断拓展诊断工具，实现更早期的检测和更精准的分期，进而辅助治疗决策。政策和采购趋势，包括关税相关影响，正推动更具策略性的采购和资本规划，以确保医疗服务的持续可近性和营运的连续性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肝癌诊断市场（依疾病分期划分）

  • 晚期
  • 早期的

第九章 肝癌诊断市场：检测类型

  • 生物标誌物
    • 遗传标记
      • ctDNA检测
      • 微型RNA检测
    • 蛋白质标记物
      • AFP侦测
      • DCP 测试
  • 切片检查
    • 核心针穿刺切片
    • 细针穿刺切片检查
  • 基因检测
    • 次世代定序
    • PCR分析

第十章 肝癌诊断市场：依技术划分

  • 电脑断层扫描
  • MRI
  • PET
  • 超音波检查

第十一章 肝癌诊断市场：依最终用户划分

  • 门诊治疗
  • 诊断中心
  • 医院
  • 研究所

第十二章 肝癌诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 肝癌诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 肝癌诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国肝癌诊断市场

第十六章：中国肝癌诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Amgen inc
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Boston Scientific Corporation
  • Danaher Corporation
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-3A2E844FE71E

The Liver Cancer Diagnostics Market was valued at USD 10.70 billion in 2025 and is projected to grow to USD 11.38 billion in 2026, with a CAGR of 6.81%, reaching USD 16.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.70 billion
Estimated Year [2026] USD 11.38 billion
Forecast Year [2032] USD 16.97 billion
CAGR (%) 6.81%

A concise overview of the shifting clinical, technological, and policy drivers that are redefining diagnostic pathways and stakeholder priorities in liver cancer care

The landscape of liver cancer diagnostics is undergoing rapid evolution driven by technological innovation, clinical practice changes, and shifting policy dynamics. This executive summary distills the most consequential developments shaping diagnosis pathways, diagnostic modality adoption, and stakeholder decision-making. The following pages synthesize clinical trends, regulatory influences, technology maturation, and operational constraints that together define the competitive and clinical milieu for diagnostic stakeholders.

The intent of this analysis is to provide an actionable synthesis that supports strategic planning across product development, commercial operations, and health system adoption. Emphasis is placed on how multi-modal diagnostic approaches are being integrated into care pathways, where evidence generation is accelerating uptake, and how payer considerations are influencing provider implementation. This section establishes the foundation for deeper insights, highlighting the interplay between diagnostic sensitivity and specificity requirements, the need for minimally invasive testing, and the push for earlier detection to enable curative-intent interventions.

Throughout the report, we prioritize clarity and relevance for leaders responsible for clinical strategy, regulatory affairs, reimbursement planning, and commercial deployment. Transitional commentary connects trends in biomarker science and imaging technology with pragmatic considerations in laboratory operations and ambulatory diagnostics, setting the stage for the more detailed thematic and regional analyses that follow.

How converging innovations in molecular diagnostics, imaging resolution, and payer-friendly evidence generation are transforming liver cancer diagnostic pathways

A confluence of transformative shifts is reshaping how liver cancer is detected, characterized, and managed. Advancements in molecular diagnostics and high-sensitivity imaging are enabling clinicians to move earlier in the disease course, improving the granularity of tumor characterization while reducing reliance on highly invasive procedures. Concurrently, the integration of circulating tumor DNA and microRNA assays with established protein markers is fostering hybrid diagnostic strategies that balance sensitivity with operational feasibility in diverse care settings.

Regulatory and reimbursement frameworks are adapting to evidence generated by real-world data and prospective validation studies, which in turn accelerates adoption when clinical utility is demonstrated. Healthcare providers are increasingly adopting multi-disciplinary diagnostic algorithms that leverage imaging modalities in parallel with targeted biomarker panels to support treatment stratification. This shift is complemented by laboratory workflow innovations and decentralized testing models that expand access in ambulatory care and diagnostic center environments.

Finally, technological convergence-where next-generation sequencing platforms, advanced bioinformatics, and higher-resolution imaging intersect-creates pathways for precision diagnostics that inform individualized therapeutic choices. These shifts collectively reduce diagnostic uncertainty, shorten time to definitive diagnosis, and generate more actionable data for oncologists, interventional radiologists, and multidisciplinary tumor boards.

Assessing how recent tariff adjustments are reshaping procurement strategies, supplier selection, and capital allocation decisions across diagnostic services and technologies

The introduction of tariffs and trade policy adjustments in 2025 has introduced new variables into procurement strategies for diagnostic consumables, imaging equipment, and molecular testing platforms. Supply chain managers and procurement leads are responding by reassessing sourcing geographies, negotiating longer-term supplier agreements, and exploring local assembly or validated secondary suppliers to mitigate exposure to import duties and associated cost volatility.

Clinicians and laboratory directors are experiencing the downstream effects of these policy changes through altered lead times for reagents, increased capital expenditure considerations for imaging hardware, and the need to justify equipment replacement cycles against a backdrop of elevated acquisition costs. In some cases, health systems are prioritizing investments in high-throughput, cost-efficient platforms that amortize tariff impacts over larger testing volumes. Others are re-evaluating capital allocation between imaging upgrades and molecular diagnostic expansion, seeking the optimal mix to sustain patient access without compromising diagnostic fidelity.

Importantly, the cumulative impact of tariff dynamics also influences strategic partnerships and licensing models. Firms with diversified manufacturing footprints and regional distribution hubs are better positioned to maintain continuity, while smaller vendors are compelled to adopt adaptive pricing strategies or localized support models. Decision-makers must therefore incorporate trade policy sensitivity analyses into procurement and product roadmaps to preserve operational resilience and maintain continuity of diagnostic services.

Granular segmentation insights reveal how disease stage, care setting, test architecture, and imaging modality collectively determine diagnostic adoption patterns and investment priorities

Segmentation-driven insight reveals distinct demand and operational patterns across disease stage, end-user profiles, test types, and technology modalities. When considering disease stage, advanced-stage workflows emphasize confirmatory testing and molecular profiling to inform targeted therapies, whereas early-stage pathways prioritize high-sensitivity screening approaches and minimally invasive diagnostics that support curative interventions. This dichotomy drives differential adoption curves for invasive versus noninvasive modalities.

Across end users, ambulatory care settings and diagnostic centers prioritize rapid turnaround, ease of sample collection, and cost-effective assays to support high-volume screening and triage; hospitals emphasize comprehensive diagnostic capabilities including image-guided biopsies and integrated molecular pathology; research laboratories focus on assay development and validation, often leveraging next-generation sequencing and investigational biomarkers to advance translational pipelines. These end-user imperatives shape procurement decisions and influence which product attributes-such as automation, throughput, and regulatory status-are prioritized in purchasing evaluations.

Test-type differentiation further clarifies market dynamics. Biomarker testing subdivides into genetic markers and protein markers, with genetic markers comprising circulating tumor DNA tests and microRNA assays, and protein markers encompassing AFP tests and DCP assays. Biopsy modalities include core needle biopsy and fine needle aspiration, each with trade-offs in tissue yield and complication risk. Genetic testing techniques span next-generation sequencing and PCR analysis, offering distinct profiles in breadth of coverage and turnaround. Imaging technologies include CT, MRI, PET, and ultrasound, with each modality delivering unique strengths in lesion detection, staging, and treatment planning. Taken together, these layered segmentation dimensions inform where investment in clinical validation, workflow integration, and payor engagement will yield the highest clinical and commercial impact.

Finally, technology-based segmentation mirrors testing categories but highlights modality-specific adoption drivers: ultrasound offers portability and cost-efficiency for screening, CT and MRI provide cross-sectional detail for staging, and PET contributes metabolic characterization that refines staging and therapeutic response assessment. Strategic initiatives that align product design and evidence generation with these segmented needs increase the likelihood of clinical adoption and sustained utilization across care settings.

Comparative regional dynamics demonstrate how healthcare infrastructure, reimbursement pathways, and capacity investments are shaping diagnostic adoption across major global markets

Regional dynamics exhibit meaningful heterogeneity driven by healthcare infrastructure, regulatory frameworks, reimbursement mechanisms, and clinical practice patterns. In the Americas, diagnostic ecosystems emphasize rapid innovation adoption within networked health systems and academic centers, fueling demand for integrated molecular and imaging solutions in tertiary hospitals and ambulatory diagnostic networks. This region often leads in the translation of clinical trial evidence into practice and demonstrates a strong appetite for advanced molecular profiling to support precision oncology initiatives.

Europe, Middle East & Africa presents a mosaic of adoption environments. Certain European markets demonstrate structured reimbursement pathways and centralized reference laboratories that facilitate standardized implementation of validated assays, while other geographies within the region contend with variability in access and resource constraints. Middle Eastern and African health systems are increasingly investing in diagnostic capacity building, with targeted initiatives to expand imaging infrastructure and laboratory capabilities that can accommodate both conventional biomarkers and emerging molecular assays.

Asia-Pacific is characterized by rapid infrastructure investment, diverse payer models, and strong domestic manufacturing capacities in select markets. High-capacity referral centers in major metropolitan areas drive demand for both high-resolution imaging and advanced genomic testing, while regional programs focused on early detection are accelerating uptake of noninvasive biomarkers. Across all regions, cross-border collaboration in clinical validation and multi-center studies is becoming a practical mechanism to generate the evidence needed for broader adoption and regulatory alignment.

Competitive and partnership dynamics reveal that integrated portfolios, robust evidence strategies, and supply chain resilience determine long-term positioning in diagnostic markets

Competitive dynamics in liver cancer diagnostics are defined by a mix of established diagnostic manufacturers, specialized molecular diagnostics firms, imaging vendors, and clinical laboratory networks. Market leaders sustain differentiated positions through broad portfolios that span imaging hardware, assay kits, and integrated software solutions that facilitate data interpretation and workflow integration. Mid-sized firms and innovative start-ups contribute by advancing niche assays, next-generation sequencing applications, and minimally invasive biomarker panels that address unmet needs in early detection and molecular subtyping.

Strategic partnerships between diagnostic developers and academic centers accelerate clinical validation and support the generation of real-world evidence necessary for guideline inclusion. Companies that invest in comprehensive clinician education, health economic dossiers, and payer engagement accrue advantages in adoption speed. Additionally, vendors that provide end-to-end solutions-encompassing sample logistics, centralized testing services, and interpretive reporting-are increasingly attractive to hospital systems and diagnostic centers seeking to minimize internal operational burden.

Supply chain resilience, regulatory preparedness, and scalability of manufacturing remain critical differentiators. Organizations that demonstrate the ability to scale reagent production, secure multi-regional regulatory clearances, and maintain service networks in clinical settings are better positioned to capture clinical partnerships and long-term contracts with health systems. For product teams and commercial leaders, the imperative is to align evidence-generation strategies with clinical workflow integration and payer pathways to translate technological advantage into durable clinical adoption.

Actionable strategic priorities for product, clinical, and commercial teams to accelerate adoption, mitigate supply risks, and demonstrate sustained clinical value

Industry leaders should prioritize a cohesive strategy that aligns product development, clinical evidence generation, and go-to-market models to maximize clinical uptake and commercial traction. Investing in prospective studies that demonstrate clinical utility in early-stage detection and treatment stratification will materially influence guideline adoption and payer support. Concurrently, companies should develop implementation roadmaps tailored to ambulatory care, diagnostic centers, hospitals, and research laboratories to ensure solutions are optimized for the operational realities of each setting.

Operationally, building flexible manufacturing footprints and regional distribution channels reduces exposure to trade-related cost fluctuations and ensures continuity of supply. Strategic collaborations with academic medical centers and large hospital networks accelerate clinical validation and create reference sites that catalyze peer adoption. On the commercial front, aligning pricing models with demonstrated health economic benefits and offering tiered service options-ranging from centralized testing to near-patient platforms-can expand addressable use cases across diverse care settings.

Finally, leaders should invest in clinician-facing education and decision-support tools that integrate molecular, protein, and imaging data into actionable reports. These tools shorten the adoption curve by reducing interpretation friction and demonstrating clear pathways from diagnostic output to therapeutic decision. Taken together, these actions will enable organizations to scale responsibly while delivering clinically meaningful improvements in patient pathways.

A mixed-methods research approach combining expert interviews, clinical literature synthesis, and technology assessments to validate operational and clinical insights

This analysis synthesizes primary and secondary evidence sources using a mixed-methods approach that balances quantitative validation with qualitative contextualization. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities and strategic intent. These perspectives were systematically coded to identify recurring themes in diagnostic adoption, workflow integration, and payer engagement.

Secondary research involved a structured review of peer-reviewed clinical literature, regulatory guidance documents, and professional society recommendations to ground insights in current standards of care and evidence thresholds. Technology assessments evaluated analytic performance characteristics, platform interoperability, and workflow considerations for molecular assays, biopsy techniques, and imaging modalities. Supply chain and policy analyses incorporated publicly available trade and procurement information to assess potential impacts on sourcing and capital investment decisions.

Where possible, findings were triangulated across multiple data streams to enhance validity. Limitations are acknowledged, including variability in regional data availability and the evolving nature of clinical validation for emerging biomarkers. To mitigate these constraints, sensitivity analyses and expert validation workshops were employed, ensuring the recommendations reflect both empirical evidence and practical feasibility for implementation across varied care settings.

Concluding synthesis emphasizing how coordinated investment in evidence generation, workflow integration, and supply resilience will shape diagnostic leadership

In summary, the diagnostic landscape for liver cancer is transitioning toward integrated, multi-modal approaches that balance sensitivity, specificity, and operational feasibility across care settings. Technological advances in genomic assays and imaging continue to expand the diagnostic toolkit, enabling earlier detection and more precise staging that inform therapeutic decision-making. Policy and procurement dynamics, including tariff-related effects, are prompting more strategic sourcing and capital planning to preserve access and operational continuity.

Segmentation analyses indicate that tailored strategies addressing the distinct needs of early versus advanced disease stages, and the specific operational constraints of ambulatory centers, hospitals, diagnostic centers, and research labs, will drive the most sustainable adoption. Regional differences underscore the importance of localized evidence generation, reimbursement alignment, and capacity-building initiatives. Competitive trajectories favor organizations that integrate robust clinical validation, scalable manufacturing, and pragmatic commercial models that lower barriers to adoption.

Collectively, these themes point to an inflection point where coordinated investment in evidence, workflow integration, and supply chain resilience will determine which technologies and providers deliver measurable clinical benefit at scale. Stakeholders that act decisively to align clinical evidence, commercial strategy, and operational readiness will be best positioned to improve diagnostic pathways and patient outcomes in liver cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Diagnostics Market, by Disease Stage

  • 8.1. Advanced Stage
  • 8.2. Early Stage

9. Liver Cancer Diagnostics Market, by Test Type

  • 9.1. Biomarkers
    • 9.1.1. Genetic Markers
      • 9.1.1.1. ctDNA Tests
      • 9.1.1.2. MicroRNA Tests
    • 9.1.2. Protein Markers
      • 9.1.2.1. AFP Tests
      • 9.1.2.2. DCP Tests
  • 9.2. Biopsy
    • 9.2.1. Core Needle Biopsy
    • 9.2.2. Fine Needle Aspiration
  • 9.3. Genetic Testing
    • 9.3.1. Next-Generation Sequencing
    • 9.3.2. PCR Analysis

10. Liver Cancer Diagnostics Market, by Technology

  • 10.1. CT Scan
  • 10.2. MRI
  • 10.3. PET
  • 10.4. Ultrasound

11. Liver Cancer Diagnostics Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
  • 11.4. Research Laboratories

12. Liver Cancer Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Cancer Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Cancer Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Liver Cancer Diagnostics Market

16. China Liver Cancer Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Amgen inc
  • 17.7. Argon Medical Devices, Inc.
  • 17.8. Bayer AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. bioMerieux SA
  • 17.12. Boston Scientific Corporation
  • 17.13. Danaher Corporation
  • 17.14. Epigenomics AG
  • 17.15. F. Hoffmann-La Roche Ltd.
  • 17.16. Hologic, Inc.
  • 17.17. Illumina, Inc.
  • 17.18. QIAGEN N.V.
  • 17.19. Siemens Healthineers AG
  • 17.20. Sysmex Corporation
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 180. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 210. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 220. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)